# Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

> **NCT07498413** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 218677 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07498413
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-08
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 218677 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498413, "Epidemiology and Treatment of HR+/HER2- Breast Cancer in England". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07498413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*